<p>2025 年 7 月 8 日- 上午 9:07</p>
<p>马萨诸塞州比勒里卡 --（商业资讯）--Quanterix Corporation（“Quanterix” 或 “公司”）（纳斯达克：QTRX），一家通过超灵敏生物标志物检测推动科学发现的公司，今天宣布已完成之前宣布的对 Akoya Biosciences, Inc.的收购，确立了在神经学、肿瘤学和免疫学市场早期疾病检测的领先地位。</p>
<p>根据 4 月 29 日宣布的修订合并协议，Quanterix 向 Akoya 的股东和其他 Akoya 股权奖励持有者发行了约 780 万股普通股，并支付了约 2000 万美元的现金，总计。</p>
<p>Quanterix 首席执行官 Masoud Toloue 博士表示：“收购 Akoya 使我们能够提供全面的蛋白质生物标志物解决方案，利用血液和组织中的特征，提供对患者疾病的更全面和预测性的视角。这笔交易将我们的产品组合扩展到新市场，并预计将我们的可服务市场从 10 亿美元扩大到 50 亿美元。我们相信，合并后的业务将受益于显著的规模、强大的资产负债表以及到 2026 年实现盈利的加速路径。”</p>
<p><strong>董事会和管理层任命</strong></p>
<p>如之前所宣布的，Masoud Toloue 和 Vandana Sriram 将继续担任合并公司的首席执行官和首席财务官。</p>
<p>根据合并协议的条款，Akoya 指定了两名董事 Scott Mendel 和 Myla Lai-Goldman 博士加入 Quanterix 董事会，Quanterix 在交易完成时任命 Mendel 先生和 Lai-Goldman 博士为其董事会成员。Mendel 先生拥有超过 30 年的财务和运营经验，最近担任 GenMark Diagnostics 的首席执行官和总裁。Lai-Goldman 博士是诊断行业的先驱和领导者，曾在 Labcorp 及其前身公司 Roche Biomedical Laboratories 担任多个领导职务。</p>
<p>Mendel 先生和 Lai-Goldman 博士将取代在交易完成前立即辞去 Quanterix 董事会职务的 Martin D. Madaus 博士和 Sarah Hlavinka。Quanterix 感谢 Madaus 博士和 Hlavinka 女士对公司的诸多贡献和奉献。</p>
<p><strong>资产负债表</strong></p>
<p>在完成 Akoya 交易时，Quanterix 在偿还 Akoya 债务和交易相关费用后，拥有约 1.63 亿美元的现金。</p>
<p><strong>关于 Quanterix</strong></p>
<p>从发现到诊断，Quanterix 的超灵敏生物标志物检测推动了只有通过其无与伦比的灵敏度和灵活性才能实现的突破。公司的 Simoa®技术为血液、血清或血浆中更早的生物标志物检测提供了黄金标准，能够量化远低于定量水平（LoQ）的蛋白质。其行业领先的精密仪器、数字免疫测定技术和 CLIA 认证的加速实验室支持了推动神经学、肿瘤学、免疫学、心脏病学和传染病领域疾病理解和管理的研究。Quanterix 在近二十年里一直是科学界值得信赖的合作伙伴，推动了在 3400 多本同行评审期刊上发表的研究。有关这家位于马萨诸塞州比勒里卡的公司的更多信息，请访问 https://www.quanterix.com 或在 Twitter 和 LinkedIn 上关注我们。</p>
<p><strong>关于前瞻性声明的警示说明</strong></p>
<p>本新闻稿中包含的非历史性或不涉及当前事实的声明旨在被视为前瞻性声明，并在此被识别为根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条所提供的安全港条款。前瞻性声明基于多种因素，包括对合并预期收益的预测，以及关于合并对 Quanterix 和 Akoya 的业务及未来财务和运营结果的影响，以及合并带来的协同效应的数量和时间。诸如 “可能”、“大约”、“继续”、“应该”、“期望”、“预测”、“预期”、“很可能”、“展望”、“相信”、“将”、“打算”、“估计”、“战略”、“计划”、“可以”、“潜在”、“可能” 等词语及其变体旨在识别此类前瞻性声明。Quanterix 提醒读者，前瞻性声明面临某些风险和不确定性，这些风险和不确定性在时间、程度、可能性和发生的程度等方面难以预测，这可能导致实际结果与预期结果存在重大差异。这些风险和不确定性包括但不限于以下可能性：对 Quanterix 或 Akoya 可能提起的任何法律诉讼的结果；合并的预期收益和协同效应未能如期或根本未能实现的可能性，包括由于两家公司整合过程中出现的问题或经济和竞争因素的影响；管理层对持续业务运营和机会的注意力分散；合并完成后可能对业务或员工关系产生的不利反应或变化；合并完成后 Quanterix 股价的变化；与合并中发行的 Quanterix 普通股可能产生的稀释效应相关的风险；以及可能影响合并公司未来结果的其他因素。可能导致结果与上述描述存在重大差异的其他因素可以在 Quanterix 截至 2024 年 12 月 31 日的年度报告（表格 10-K）及 Quanterix 向 SEC 提交的其他文件中找到，这些文件可在 SEC 网站 www.sec.gov 上获取。</p>
<p>本新闻稿中所包含的所有前瞻性声明，无论是明示还是暗示，均受到此处包含或提及的警示性声明的完全限制。如果与这些或其他风险或不确定性相关的一个或多个事件发生，或者 Quanterix 的基本假设被证明不正确，实际结果可能与 Quanterix 的预期存在重大差异。Quanterix 提醒读者不要对任何此类前瞻性声明过度依赖，这些声明仅在作出时有效，并基于当时可用的信息。除非联邦证券法要求，Quanterix 不承担更新或以其他方式修订任何前瞻性声明的义务，以反映前瞻性声明作出后发生的情况或事件，或反映意外事件的发生。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MDc4MjgwNThyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MDc4MjgwNThyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20250707828058/en/</p>
<p>媒体</p>
<p>Marissa Klaassen</p>
<p>media@quanterix.com</p>
<p>投资者关系</p>
<p>Joshua Young</p>
<p>ir@quanterix.com</p>
<p>来源：Quanterix Corporation</p>

AKYA

QTRX

<p>Quanterix Corporation 已完成对 Akoya Biosciences 的收购，增强了其在神经学、肿瘤学和免疫学领域的生物标志物检测能力。该交易涉及发行约 780 万股股票并支付 2000 万美元现金。预计此次收购将使 Quanterix 的市场规模从 10 亿美元扩大至 50 亿美元，并在 2026 年之前加速盈利能力。关键任命包括 Scott Mendel 和 Dr. Myla Lai-Goldman 加入董事会。Quanterix 在交易后报告现金为 1.63 亿美元，为未来增长奠定了基础</p>

<p>07/08/2025 - 09:07 AM</p>
<div class="lb-trans"><p>2025 年 7 月 8 日- 上午 9:07</p>
</div><p>BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced that it has completed its previously announced acquisition of Akoya Biosciences, Inc., establishing a scaled leader in the early detection of disease for the neurology, oncology and immunology markets.</p>
<div class="lb-trans"><p>马萨诸塞州比勒里卡 --（商业资讯）--Quanterix Corporation（“Quanterix” 或 “公司”）（纳斯达克：QTRX），一家通过超灵敏生物标志物检测推动科学发现的公司，今天宣布已完成之前宣布的对 Akoya Biosciences, Inc.的收购，确立了在神经学、肿瘤学和免疫学市场早期疾病检测的领先地位。</p>
</div><p>Under the terms of the amended merger agreement announced on April 29th, Quanterix issued approximately 7.8 million shares of its common stock and paid approximately $20 million in cash, in the aggregate, to holders of Akoya shares and other Akoya equity awards.</p>
<div class="lb-trans"><p>根据 4 月 29 日宣布的修订合并协议，Quanterix 向 Akoya 的股东和其他 Akoya 股权奖励持有者发行了约 780 万股普通股，并支付了约 2000 万美元的现金，总计。</p>
</div><p>Masoud Toloue, PhD, Chief Executive Officer of Quanterix, said, “The acquisition of Akoya positions us to deliver comprehensive protein biomarker solutions that leverage signatures in blood and tissue, together providing a more holistic and predictive view of a patient’s disease. This transaction extends our portfolio into new markets and is expected to expand our served addressable market from $1 billion to $5 billion. We believe the combined business will benefit from significant scale, a strong balance sheet and an accelerated path to profitability by 2026.”</p>
<div class="lb-trans"><p>Quanterix 首席执行官 Masoud Toloue 博士表示：“收购 Akoya 使我们能够提供全面的蛋白质生物标志物解决方案，利用血液和组织中的特征，提供对患者疾病的更全面和预测性的视角。这笔交易将我们的产品组合扩展到新市场，并预计将我们的可服务市场从 10 亿美元扩大到 50 亿美元。我们相信，合并后的业务将受益于显著的规模、强大的资产负债表以及到 2026 年实现盈利的加速路径。”</p>
</div><p><strong>Board and Management Appointments</strong></p>
<div class="lb-trans"><p><strong>董事会和管理层任命</strong></p>
</div><p>As previously announced, Masoud Toloue and Vandana Sriram will continue to serve as Chief Executive Officer and Chief Financial Officer of the combined company.</p>
<div class="lb-trans"><p>如之前所宣布的，Masoud Toloue 和 Vandana Sriram 将继续担任合并公司的首席执行官和首席财务官。</p>
</div><p>Pursuant to the terms of the merger agreement, Akoya designated two of its directors, Scott Mendel and Myla Lai-Goldman, MD, to join the Quanterix Board of Directors, and Quanterix appointed Mr. Mendel and Dr. Lai-Goldman to its Board of Directors, effective at the closing of the transaction. Mr. Mendel brings over 30 years of financial and operational experience, most recently having served as CEO and President of GenMark Diagnostics. Dr. Lai-Goldman is a pioneer and leader in the diagnostics industry and has held various leadership roles at Labcorp and its predecessor company, Roche Biomedical Laboratories.</p>
<div class="lb-trans"><p>根据合并协议的条款，Akoya 指定了两名董事 Scott Mendel 和 Myla Lai-Goldman 博士加入 Quanterix 董事会，Quanterix 在交易完成时任命 Mendel 先生和 Lai-Goldman 博士为其董事会成员。Mendel 先生拥有超过 30 年的财务和运营经验，最近担任 GenMark Diagnostics 的首席执行官和总裁。Lai-Goldman 博士是诊断行业的先驱和领导者，曾在 Labcorp 及其前身公司 Roche Biomedical Laboratories 担任多个领导职务。</p>
</div><p>Mr. Mendel and Dr. Lai-Goldman will replace Martin D. Madaus, PhD, and Sarah Hlavinka, who have resigned from the Quanterix Board of Directors as of immediately prior to the closing of the transaction. Quanterix thanks Dr. Madaus and Ms. Hlavinka for their numerous contributions and dedication to the Company.</p>
<div class="lb-trans"><p>Mendel 先生和 Lai-Goldman 博士将取代在交易完成前立即辞去 Quanterix 董事会职务的 Martin D. Madaus 博士和 Sarah Hlavinka。Quanterix 感谢 Madaus 博士和 Hlavinka 女士对公司的诸多贡献和奉献。</p>
</div><p><strong>Balance Sheet</strong></p>
<div class="lb-trans"><p><strong>资产负债表</strong></p>
</div><p>At the time of closing the Akoya transaction, Quanterix had approximately $163 million in cash after repayment of Akoya’s debt and transaction-related costs.</p>
<div class="lb-trans"><p>在完成 Akoya 交易时，Quanterix 在偿还 Akoya 债务和交易相关费用后，拥有约 1.63 亿美元的现金。</p>
</div><p><strong>About Quanterix</strong></p>
<div class="lb-trans"><p><strong>关于 Quanterix</strong></p>
</div><p>From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.</p>
<div class="lb-trans"><p>从发现到诊断，Quanterix 的超灵敏生物标志物检测推动了只有通过其无与伦比的灵敏度和灵活性才能实现的突破。公司的 Simoa®技术为血液、血清或血浆中更早的生物标志物检测提供了黄金标准，能够量化远低于定量水平（LoQ）的蛋白质。其行业领先的精密仪器、数字免疫测定技术和 CLIA 认证的加速实验室支持了推动神经学、肿瘤学、免疫学、心脏病学和传染病领域疾病理解和管理的研究。Quanterix 在近二十年里一直是科学界值得信赖的合作伙伴，推动了在 3400 多本同行评审期刊上发表的研究。有关这家位于马萨诸塞州比勒里卡的公司的更多信息，请访问 https://www.quanterix.com 或在 Twitter 和 LinkedIn 上关注我们。</p>
</div><p><strong>Cautionary Statement Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>关于前瞻性声明的警示说明</strong></p>
</div><p>Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on, among other things, projections as to the anticipated benefits of the merger as well as statements regarding the impact of the merger on Quanterix’s and Akoya’s business and future financial and operating results and the amount and timing of synergies from the merger. Words and phrases such as “may,” “approximately,” “continue,” “should,” “expects,” “projects,” “anticipates,” “is likely,” “look ahead,” “look forward,” “believes,” “will,” “intends,” “estimates,” “strategy,” “plan,” “could,” “potential,” “possible” and variations of such words and similar expressions are intended to identify such forward-looking statements. Quanterix cautions readers that forward-looking statements are subject to certain risks and uncertainties that are difficult to predict with regard to, among other things, timing, extent, likelihood and degree of occurrence, which could cause actual results to differ materially from anticipated results. Such risks and uncertainties include, among others, the following possibilities: the outcome of any legal proceedings that may be instituted against Quanterix or Akoya; the possibility that the anticipated benefits and synergies of the merger are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of the strength of the economy and competitive factors in the areas where Quanterix and Akoya do business; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the completion of the merger; changes in Quanterix’s share price after the closing of the merger; risks relating to the potential dilutive effect of shares of Quanterix common stock issued in the merger; and other factors that may affect future results of the combined company. Additional factors that could cause results to differ materially from those described above can be found in Quanterix’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and in other documents Quanterix files with the SEC, which are available on the SEC’s website at www.sec.gov.</p>
<div class="lb-trans"><p>本新闻稿中包含的非历史性或不涉及当前事实的声明旨在被视为前瞻性声明，并在此被识别为根据《1933 年证券法》第 27A 条及《1934 年证券交易法》第 21E 条所提供的安全港条款。前瞻性声明基于多种因素，包括对合并预期收益的预测，以及关于合并对 Quanterix 和 Akoya 的业务及未来财务和运营结果的影响，以及合并带来的协同效应的数量和时间。诸如 “可能”、“大约”、“继续”、“应该”、“期望”、“预测”、“预期”、“很可能”、“展望”、“相信”、“将”、“打算”、“估计”、“战略”、“计划”、“可以”、“潜在”、“可能” 等词语及其变体旨在识别此类前瞻性声明。Quanterix 提醒读者，前瞻性声明面临某些风险和不确定性，这些风险和不确定性在时间、程度、可能性和发生的程度等方面难以预测，这可能导致实际结果与预期结果存在重大差异。这些风险和不确定性包括但不限于以下可能性：对 Quanterix 或 Akoya 可能提起的任何法律诉讼的结果；合并的预期收益和协同效应未能如期或根本未能实现的可能性，包括由于两家公司整合过程中出现的问题或经济和竞争因素的影响；管理层对持续业务运营和机会的注意力分散；合并完成后可能对业务或员工关系产生的不利反应或变化；合并完成后 Quanterix 股价的变化；与合并中发行的 Quanterix 普通股可能产生的稀释效应相关的风险；以及可能影响合并公司未来结果的其他因素。可能导致结果与上述描述存在重大差异的其他因素可以在 Quanterix 截至 2024 年 12 月 31 日的年度报告（表格 10-K）及 Quanterix 向 SEC 提交的其他文件中找到，这些文件可在 SEC 网站 www.sec.gov 上获取。</p>
</div><p>All forward-looking statements, expressed or implied, included in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or other risks or uncertainties materialize, or if Quanterix’s underlying assumptions prove to be incorrect, actual results may differ materially from what Quanterix anticipates. Quanterix cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and are based on information available at that time. Quanterix does not assume any obligation to update or otherwise revise any forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements were made or to reflect the occurrence of unanticipated events except as required by federal securities laws.</p>
<div class="lb-trans"><p>本新闻稿中所包含的所有前瞻性声明，无论是明示还是暗示，均受到此处包含或提及的警示性声明的完全限制。如果与这些或其他风险或不确定性相关的一个或多个事件发生，或者 Quanterix 的基本假设被证明不正确，实际结果可能与 Quanterix 的预期存在重大差异。Quanterix 提醒读者不要对任何此类前瞻性声明过度依赖，这些声明仅在作出时有效，并基于当时可用的信息。除非联邦证券法要求，Quanterix 不承担更新或以其他方式修订任何前瞻性声明的义务，以反映前瞻性声明作出后发生的情况或事件，或反映意外事件的发生。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTA3MDc4MjgwNThyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20250707828058r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20250707828058/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20250707828058/en/</p>
</div><p>Media</p>
<div class="lb-trans"><p>媒体</p>
</div><p>Marissa Klaassen</p>
<div class="lb-trans"><p>Marissa Klaassen</p>
</div><p>media@quanterix.com</p>
<div class="lb-trans"><p>media@quanterix.com</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投资者关系</p>
</div><p>Joshua Young</p>
<div class="lb-trans"><p>Joshua Young</p>
</div><p>ir@quanterix.com</p>
<div class="lb-trans"><p>ir@quanterix.com</p>
</div><p>Source: Quanterix Corporation</p>
<div class="lb-trans"><p>来源：Quanterix Corporation</p>
</div>

Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum | QTRX Stock News

Quanterix 完成了对 Akoya Biosciences 的收购，打造了首个能够在血液和组织连续体中测量生物标志物的综合平台 | QTRX 股票新闻